Previous 10 | Next 10 |
ATHENA study evaluating Rubraca monotherapy versus placebo (ATHENA-MONO) successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all patients randomized (ITT) Median PFS of 20.2 months for Rubraca vs 9...
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the initiation of a development, manufacturing, and services agreement with Evergreen Theragnostics to develop actinium-225-labeled-FAP-2286 ( 225 Ac-FAP-2286). Under the agreement, Clovis and Evergreen intend to develop radiolabe...
3 Hot Penny Stocks to Add to Your Watchlist in Mid-March When you are looking to invest in penny stocks, it is important to do your research first. Not all penny stocks are created equal, and some are much riskier than others. There are a few things to keep in mind when looking for pe...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced a Trial-in-Progress poster detailing the Phase 1 portion of the LuMIERE clinical study for its targeted radiotherapy candidate FAP-2286 and a presentation titled “Initial Experience with FAP-2286 Imaging” related to an o...
Clovis Oncology, Inc. (CLVS) Q4 2021 Earnings Conference Call February 23, 2022 8:30 AM ET Company Participants Anna Sussman – Vice President-Investor Relations and Corporate Communications Patrick Mahaffy – President and Chief Executive Officer Thomas Harding – Chief Sci...
Clovis Oncology (CLVS -4.4%) saw its net loss narrow ~19% in Q4 2021 compared to the prior-year period even as revenue declined. Net loss for Q4 was ~$64.4M, or -$0.50 per basic and diluted shares. Product revenue was ~$36M, a 17% decline from the year-ago period. For full-year 2021, Rubraca&...
The following slide deck was published by Clovis Oncology, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Clovis Oncology, Inc. 2021 Q4 - Results - Earnings Call Presentation
Clovis Oncology press release (NASDAQ:CLVS): Q4 GAAP EPS of -$0.50. Revenue of $35.97M (-16.9% Y/Y). “We have been looking forward to 2022 for a long time, which we anticipate will be the most significant year for clinical data read-outs in the Company’s history,” said...
Three top-line Phase 3 data read-outs for Rubraca expected in 2022, with potential to address larger ovarian and prostate cancer patient populations in earlier lines of therapy Phase 1/2 LuMIERE study of targeted radiotherapy candidate FAP-2286 ongoing; initial Phase 1 d...
News, Short Squeeze, Breakout and More Instantly...
Receives Commitment for up to $75 Million in Debtor-in-Possession Financing Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., E...